As a prospective investor we invite you to join us for a live Q&A webcast where we will discuss our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™/AniGel™ and then jump right into your questions.
Update: This webinar date has passed, however, the recording is available for you to view here:
As a prospective investor we invite you to join us for a special webcast with guest Dr. Jake Hutchins on the significance of AnestaGel in preclinical studies.
About Dr. Hutchins: Medical Director, University of Minnesota Health Acute Pain Service (2012-present), Medical Director, University of Minnesota Health Sports and Ambulatory Surgery Center (2014-present), Director, Perioperative and Interventional Pain Service (PIPS), Editor, Practical Reviews in Anesthesiology (2012-present), Member, Pain Steering Committee (2012-present).
Update: This webinar date has passed, however, the recording is now available to view here:
As a prospective investor we invite you to join us for a live Q&A webcast where we will discuss our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™/AniGel™ and then jump right into your questions.
Update: This webinar date has passed, however, the recording is available for you to view here:
Tier 4 of the offering has officially closed and we have qualification from the SEC to sell our shares at the price of $8.20 per share. We are now offering 50,000 shares at this price with a minimum purchase of 300 shares per investment.
As a prospective investor we invite you to join us for a live Q&A webcast where we will discuss our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™/AniGel™ and then jump right into your questions.
Update: This event has passed, however, you can now view the recording here:
As a prospective investor we invite you to join us for a live Q&A webcast where we will discuss our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™/AniGel™ and then jump right into your questions.
Update: This webinar date has passed, however, the recording is available for you to view here:
An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement, which only means that the company may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement from here.
https://www.manhattanstreetcapital.com/sites/default/files/Insitu_Offering_Circular_10-19-19.pdf
You should read the offering circular before making any investment.
The offering materials may contain forward-looking statements and information relating to, among other things, Insitu Biologics, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify and constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
Securities are offered through Sageworks Capital, LLC., a registered broker-dealer and member FINRA/SIPC. Neither InSitu Biologics, Inc. nor Sageworks Capital, LLC provides any investment advice or make any investment recommendations to any persons, ever, and no communication through this website or in any other medium should be construed as such.
InSitu Biologics, Inc. securities are not publicly traded and are intended for investors who do not need a liquid investment. This investment is NOT a bank deposit (and thus NOT insured by the FDIC or by any other federal governmental agency), are NOT guaranteed by Sageworks Capital, LLC or InSitu Biologics, Inc., and MAY lose value. Investors must be able to afford the loss of their entire investment.
Any financial projections or returns shown on the website are illustrative examples only, and there can be no assurance that any valuations provided are accurate or in agreement with market or industry valuations. Investors should conduct their own due diligence, not rely on the financial assumptions or estimates displayed on this website, and are encouraged to consult with a financial advisor, attorney, accountant, and any other professional that can help you to understand and assess the risks associated with any investment opportunity. Please refer to the offering circular for full details and disclosures, including a subscription agreement should you choose to invest.
Insitu Biologics, Inc. is required to pay an advisory retainer fee of $6,000, plus the same value of warrants at the respective issue price. In addition, they will pay a technology admin and service fee of $25 per investor, plus the same value of warrants at the respective issue price. As of 11/30/2018 Insitu Biologics has paid $24,000 in fees.
